Table 3.

Breast Swelling

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit+)
POST OP	Overall Breast Swelling (N=320)	172 (53.8%)	121 (37.8%)	19 (5.9%)	8 (2.5%)
	Vs Arm (N=320)					0.324	0.476
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=66)	33 (50.0%)	29 (43.9%)	2 (3.0%)	2 (3.0%)
	AC (Doxorubicin and Cyclophosphamide) (N=99)	49 (49.5%)	43 (43.4%)	4 (4.0%)	3 (3.0%)
	Capecitabine (N=155)	90 (58.1%)	49 (31.6%)	13 (8.4%)	3 (1.9%)
	Vs Most Extensive Surgery (N=318)					0.981	0.395
	Breast Conserving Surgery (N=143)	77 (53.8%)	56 (39.2%)	6 (4.2%)	4 (2.8%)
	Full Mastectomy (N=175)	94 (53.7%)	64 (36.6%)	13 (7.4%)	4 (2.3%)
	Vs Axillary Dissection (N=320)					0.091	0.463
	No (N=65)	41 (63.1%)	20 (30.8%)	2 (3.1%)	2 (3.1%)
	Yes (N=255)	131 (51.4%)	101 (39.6%)	17 (6.7%)	6 (2.4%)
	Vs RT (N=300)					0.029	0.507
	No (N=139)	84 (60.4%)	45 (32.4%)	9 (6.5%)	1 (0.7%)
	Yes (N=161)	77 (47.8%)	69 (42.9%)	9 (5.6%)	6 (3.7%)
	Vs Number of Nodes Examined (N=313)					0.065	0.562
	0-3 (N=49)	33 (67.3%)	13 (26.5%)	1 (2.0%)	2 (4.1%)
	4-7 (N=53)	31 (58.5%)	19 (35.8%)	1 (1.9%)	2 (3.8%)
	8+ (N=211)	105 (49.8%)	86 (40.8%)	16 (7.6%)	4 (1.9%)
AT 12 MONTHS	Overall Breast Swelling (N=257)	225 (87.5%)	25 (9.7%)	5 (1.9%)	2 (0.8%)
	Vs Arm (N=257)					0.764	0.452
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)	48 (88.9%)	5 (9.3%)	0 (0%)	1 (1.9%)
	AC (Doxorubicin and Cyclophosphamide) (N=82)	73 (89.0%)	8 (9.8%)	1 (1.2%)	0 (0%)
	Capecitabine (N=121)	104 (86.0%)	12 (9.9%)	4 (3.3%)	1 (0.8%)
	Vs Most Extensive Surgery (N=255)					0.329	0.028
	Breast Conserving Surgery (N=115)	98 (85.21%)	11 (9.6%)	5 (4.3%)	1 (0.9%)
	Full Mastectomy (N=140)	125 (89.3%)	14 (10.0%)	0 (0%)	1 (0.7%)
	Vs Axillary Dissection (N=257)					0.076	0.691
	No (N=55)	52 (94.5%)	2 (3.6%)	1 (1.8%)	0 (0%)
	Yes (N=202)	173 (85.6%)	23 (11.4%)	4 (2.0%)	2 (1.0%)
	Vs RT (N=243)					0.011	0.013
	No (N=109)	102 (93.6%)	7 (6.4%)	0 (0%)	0 (0%)
	Yes (N=134)	111 (82.8%)	16 (11.9%)	5 (3.7%)	2 (1.5%)
	Vs Number of Nodes Examined (N=252)					0.097	0.172
	0-3 (N=43)	41 (95.3%)	1 (2.3%)	1 (2.3%)	0 (0%)
	4-7 (N=39)	31 (79.5%)	5 (12.8%)	1 (2.6%)	2 (5.1%)
	8+ (N=170)	148 (87.1%)	19 (11.2%)	3 (1.8%)	0 (0%)
AT 24 MONTHS	Overall Breast Swelling (N=240)	217 (90.4%)	21 (8.8%)	1 (0.4%)	1 (0.4%)
	Vs Arm (N=240)					0.742	0.363
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	43 (87.8%)	5 (10.2%)	0 (0%)	1 (2.0%)
	AC (Doxorubicin and Cyclophosphamide) (N=83)	75 (90.4%)	7 (8.4%)	1 (1.2%)	0 (0%)
	Capecitabine (N=108)	99 (91.7%)	9 (8.3%)	0 (0%)	0 (0%)
	Vs Most Extensive Surgery (N=238)					0.804	0.201
	Breast Conserving Surgery (N=108)	97 (89.8%)	11 (10.2%)	0 (0%)	0 (0%)
	Full Mastectomy (N=130)	118 (90.8%)	10 (7.7%)	1 (0.8%)	1 (0.8%)
	Vs Axillary Dissection (N=240)					0.112	0.475
	No (N=52)	50 (96.2%)	2 (3.8%)	0 (0%)	0 (0%)
	Yes (N=188)	167 (88.8%)	19 (10.1%)	1 (0.5%)	1 (0.5%)
	Vs RT (N=226)					0.551	0.919
	No (N=100)	92 (92.0%)	7 (7.0%)	1 (1.0%)	0 (0%)
	Yes (N=126)	113 (89.7%)	12 (9.5%)	0 (0%)	1 (0.8%)
	Vs Number of Nodes Examined (N=236)					0.509	0.425
	0-3 (N=41)	39 (95.1%)	2 (4.9%)	0 (0%)	0 (0%)
	4-7 (N=39)	35 (89.7%)	3 (7.7%)	0 (0%)	1 (2.6%)
	8+ (N=156)	139 (89.1%)	16 (10.3%)	1 (0.6%)	0 (0%)